☆ 4.5 Article

Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies

TRANSPLANT INTERNATIONAL (2022)

Related references

Note: Only part of the references are listed.

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Add to Collection

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Elisabetta Cameroni et al.

Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.

NATURE (2022)

Add to Collection

Article Immunology

Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients

Saima Aslam et al.

Summary: This study examined the clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. The results showed that receiving two doses of mRNA COVID-19 vaccines provided significant protection against symptomatic COVID-19.

TRANSPLANT INFECTIOUS DISEASE (2022)

Add to Collection

Editorial Material Immunology

SARS-CoV-2 vaccine clinical efficacy in SOT: What we know and our current gaps

Rachel Sigler et al.

TRANSPLANT INFECTIOUS DISEASE (2022)

Add to Collection

Article Immunology

Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients

Bonnie Ann Sarrell et al.

Summary: Studies suggest that early intervention with monoclonal antibody treatment directed against the SARS-CoV-2 spike protein may reduce the risk of emergency department visits or hospitalization for COVID-19 in solid organ transplant recipients. Our experience indicates that monoclonal antibody treatment may provide favorable outcomes for mild to moderate COVID-19 in SOT recipients during the study period with available formulations and viral variants.

TRANSPLANT INFECTIOUS DISEASE (2022)

Add to Collection

Article Surgery

Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic

Madeleine R. Heldman et al.

Summary: Mortality among solid organ transplant recipients hospitalized for COVID-19 decreased between early and late 2020, with the late period showing lower mortality even after adjusting for baseline comorbidities. The use of corticosteroids and remdesivir increased, while the use of hydroxychloroquine and IL-6/IL-6 receptor inhibitors decreased between the two periods.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Medicine, General & Internal

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study

Cristina Menni et al.

Summary: This study investigated the differences in symptom prevalence, risk of hospital admission, and symptom duration between omicron and delta variants of the SARS-CoV-2 virus. The study found that loss of smell was less common in omicron infections, sore throat was more common, and the rate of hospital admission was lower.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Tommy Nyberg et al.

Summary: The Omicron variant shows lower severity compared to Delta, especially in terms of hospital admission and death, with significant variations by age. Unvaccinated cases experience a larger reduction in intrinsic severity, while vaccinated cases experience reduced vaccine effectiveness. Booster vaccination with mRNA vaccines provides over 70% protection against hospitalization and death in breakthrough Omicron infections.

LANCET (2022)

Add to Collection

Letter Immunology

Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients

Chloe Dimeglio et al.

TRANSPLANTATION (2022)

Add to Collection

Article Oncology

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Michel Obeid et al.

Summary: After vaccination with mRNA vaccines, the neutralizing antibody responses in immunocompromised patients and healthy controls have shown a decline at 6 months. These findings may provide insights for the development of optimal booster vaccination schedules, especially for immunocompromised patients.

JAMA ONCOLOGY (2022)

Add to Collection

Article Urology & Nephrology

Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients

Juliette Gueguen et al.

Summary: This study found that the early use of MoAb significantly improved clinical outcomes in KTRs, reducing the incidence of COVID-19-related hospitalization, admission to ICU within 30 days, and death within 30 days.

KIDNEY INTERNATIONAL REPORTS (2022)

Add to Collection

Review Microbiology

Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis

Kaiming Tao et al.

Summary: The susceptibility of authorized monoclonal antibodies (MAbs) to the SARS-CoV-2 Omicron variants is not yet clear and results from studies are inconsistent. According to the findings of 51 studies, several authorized MAbs show reduced activity against the Omicron variants. Improvements in MAb susceptibility test standardization are needed to accurately assess their effectiveness against the Omicron variants.

MICROBIOLOGY SPECTRUM (2022)

Add to Collection

Article Surgery

COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies

Abhay Dhand et al.

Summary: The use of anti-SARS-CoV-2 monoclonal antibodies in high-risk solid organ transplant recipients is associated with a reduction in the risk of hospitalization, need for intensive care, and death related to COVID-19. Early experiences from diverse transplant recipients show promising results with no reported acute graft injury, severe adverse events, or deaths related to COVID-19.

CURRENT TRANSPLANTATION REPORTS (2022)

Add to Collection

Review Surgery

Impact of COVID-19 in solid organ transplant recipients

Lara Danziger-Isakov et al.

Summary: The COVID-19 pandemic in 2020 had a significant impact on organ transplantation globally, leading to decreased donations and increased pressure due to limited medical resources.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Surgery

Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience

Abhay Dhand et al.

CLINICAL TRANSPLANTATION (2021)

Add to Collection

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Surgery

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Ayelet Grupper et al.

Summary: Only 37.5% of transplant recipients developed a positive immune response to the Pfizer vaccine, with lower antibody levels, and factors associated with null immune response include older age, high-dose corticosteroids use, triple immunosuppression maintenance, and regimen with mycophenolate.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Medicine, General & Internal

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Immunology

Casirivimab-Imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients

Abhay Dhand et al.

TRANSPLANTATION (2021)

Add to Collection

Article Virology

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

Johannes Korth et al.

Summary: Research has shown that renal transplant recipients have impaired immune response after receiving two doses of mRNA-based vaccine, with significantly lower antibody levels compared to healthy controls.

VIRUSES-BASEL (2021)

Add to Collection

Article Immunology

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh et al.

Summary: This study compared the outcomes of high-risk patients who received bamlanivimab and casirivimab-imdevimab, showing similarly low rates of all-cause and COVID-19-related hospitalizations. Factors associated with higher likelihood of hospitalization included chronic kidney, respiratory, and cardiovascular diseases, as well as immunocompromised status.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients

Saima Aslam et al.

Summary: The study found that COVID-19 vaccination significantly reduced the incidence of symptomatic COVID-19 in solid organ transplant recipients, demonstrating real-world clinical effectiveness.

TRANSPLANT INFECTIOUS DISEASE (2021)

Add to Collection

Article Immunology

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar et al.

Summary: This study retrospectively reviewed solid organ transplant recipients who received monoclonal antibody treatment for COVID-19, showing favorable outcomes and minimal adverse effects in this patient population. Early administration of monoclonal antibody therapy appears to be more efficacious.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern

Marco Falcone et al.

Summary: This study aimed to evaluate the risk of hospitalization or death in patients infected by SARS-CoV2 variants of concern receiving combinations of monoclonal antibodies. The results showed that in patients infected by the SARS-CoV-2 Gamma variant, the use of bamlanivimab/etesevimab should be used with caution due to the high risk of disease progression.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection

Article Medicine, Research & Experimental

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Arne Sattler et al.

Summary: The study analyzed immune responses in kidney transplant recipients after receiving the BNT162b2 vaccine, finding weaker antibody responses in transplant patients compared to healthy individuals and most hemodialysis patients. Additionally, spike-specific T cell responses were significantly reduced in transplant patients, indicating a need for revised vaccination strategies in immunosuppressed individuals.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Review Immunology

COVID-19 and Solid Organ Transplantation: A Review Article

Yorg Azzi et al.

Summary: Solid organ transplantation has been significantly impacted by the coronavirus pandemic, with high mortality rates reported in recipients. The pandemic led to complexities in transplantation, including new questions regarding donor and recipient screening, and decisions on continuing transplantation based on clinical implications of COVID-19 infection. The clinical outcomes of COVID-19 in transplantation may vary depending on the type of transplanted organ and recipient comorbidities.

TRANSPLANTATION (2021)

Add to Collection

Article Virology

Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies

Craig Fenwick et al.

Summary: In this study, antibody responses to SARS-CoV-2 were evaluated in acute and postinfection subjects. The results show that responses against viral S and N proteins were equally sensitive in acute phase, but N responses decreased in postinfection phase while S responses persisted. The most sensitive assay used the native S protein trimer, suggesting its importance in estimating SARS-CoV-2 infections and assessing vaccine-induced responses.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Article Immunology

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar et al.

Summary: Monoclonal antibody therapy for COVID-19 appears to be safe and effective with favorable outcomes in solid organ transplant recipients, with earlier administration associated with reduced hospitalizations. No episodes of rejection or anaphylaxis were reported.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Surgery

First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

Jonathan Tschopp et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2020)

Add to Collection

Article Computer Science, Interdisciplinary Applications

The REDCap consortium: Building an international community of software platform partners

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2019)

Add to Collection

Article Computer Science, Interdisciplinary Applications

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.